ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM – 12 April 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Read More
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrint® is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial IRVINE, CA and AMSTERDAM, 21 March 2017 – Agendia, a world leader in Read More
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer IRVINE, CA and AMSTERDAM – Read More
Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award
Significant clinical benefit of Agendia’s MammaPrint® test and other advances in the improved treatment of breast cancer recognized at ceremony during ECCO2017 IRVINE, CA and AMSTERDAM – 30 January 2017 – Agendia, Inc., a world Read More